mAbxience and Corapharm Partner to Expand Biosimilar Access in Southeast Europe

• mAbxience and Corapharm have entered a strategic licensing agreement to develop and commercialise a biosimilar in Southeast Europe.

• The deal covers multiple countries, with mAbxience responsible for development and manufacturing and Corapharm leading commercialisation.

mAbxience, a majority-owned company of Fresenius Kabi and partially owned by Insud Pharma, has announced a new strategic licensing agreement with Corapharm to develop and commercialise a biosimilar candidate in Southeast Europe.

Under the terms of the agreement, mAbxience will retain marketing authorisation in Croatia and Slovenia, while Corapharm will hold this responsibility in Serbia, Bosnia and Herzegovina, North Macedonia, Montenegro, Kosovo, and Albania. Corapharm will lead the commercialisation strategy across these territories, while mAbxience manages development and manufacturing from its advanced production facilities.

The collaboration aims to broaden patient access to biosimilar therapies and support regional healthcare systems in managing the increasing costs of biologics. The companies will combine Corapharm’s local market expertise with mAbxience’s manufacturing capabilities to meet growing demand for high-quality, affordable treatments.

“We are excited to partner with Corapharm to bring this biosimilar candidate to patients across Southeast Europe,” said José Ramón Millán, Global Partnering & Portfolio Director at mAbxience.

Mr. Miroslav Roca, CEO of Corapharm d.o.o., said the company looks forward to working with mAbxience to improve patient outcomes and widen access to essential treatments: “Together, we remain dedicated to enhancing patient care and addressing the rising costs of biologic therapies.”